New dosing schedule could ease sickle cell treatment for kids

NCT ID NCT06578507

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study is testing whether giving hydroxyurea twice a day works better than the usual once-daily dose for children with sickle cell disease. About 50 children aged 9 months to 11 years will take the drug for 12 months. Researchers will measure how the drug behaves in the body and whether it helps control the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Hydroxyurea (hydroxycarbamide) dispersible tablets
What this could lead to
If successful, this could offer a more convenient twice-daily dosing option for children with sickle cell disease, potentially improving adherence and disease control.
What could go wrong
This is a small, early-phase study with only 50 children and no comparison group. It may not show clear benefits, and side effects like bone marrow suppression are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre Hospitalier Intercommunal Créteil

    RECRUITING

    Créteil, France

  • Centre hospitalier de Cayenne

    RECRUITING

    Cayenne, French Guiana

  • GHEF- Site de Marne-la-Vallée

    RECRUITING

    Jossigny, France

  • Hôpital Bicêtre

    RECRUITING

    Le Kremlin-Bicêtre, France

  • Hôpital Necker-Enfants malades

    RECRUITING

    Paris, France

  • Institut d'Hématologie et d'oncologie pédiatrique - IHOPe

    ACTIVE_NOT_RECRUITING

    Lyon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.